| Palexia RP (tapentadol extended release) / Assertio, J&J, Grunenthal, Collegium Pharma |
NCT00745069: Efficacy and Safety of Tapentadol Extended Release Tablets in the Treatment of Moderate to Severe Pain in Subjects With Knee Osteoarthritis |
|
|
| Completed | 2b | 670 | US | tapentadol HCl | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Grünenthal GmbH | Osteoarthitis, Chronic Pain, Knee Pain | | 08/05 | | |
NCT00805142: Phase 2 Study of Tapentadol Prolonged Release in Cancer Pain Participants |
|
|
| Completed | 2 | 78 | Japan | Tapentadol PR, Tapentadol hydrochloride, JNS024 | Janssen Pharmaceutical K.K., Grünenthal GmbH | Pain, Cancer | 07/09 | 07/09 | | |
NCT01124604: An Efficacy and Safety Study for Tapentadol Extended Release (JNS024ER) in Chronic Pain Participants |
|
|
| Completed | 2 | 91 | Japan | Tapentadol Hydrochloride, Placebo | Janssen Pharmaceutical K.K. | Pain, Low Back Pain, Back Pain, Osteoarthritis, Knee | 12/10 | 12/10 | | |
NCT01124617: A Phase 2 Study of Tapentadol Extended-Release (JNS024ER) ) in Japanese Participants With Chronic Pain Due to Diabetic Neuropathic Pain or Postherpetic Neuralgia |
|
|
| Completed | 2 | 91 | Japan | Tapentadol, JNS024ER, Placebo | Janssen Pharmaceutical K.K. | Pain, Diabetic Neuropathies, Neuralgia, Postherpetic Neuralgia | 04/11 | 04/11 | | |
2012-003770-11: A multi-center, randomized parallel group pilot study to investigate the mechanism of action of tapentadol PR and oxycodone CR in subjects with osteoarthritis knee pain |
|
|
| Ongoing | 2 | 60 | Europe | Palexia Depot, OxyContin, Palexia Depot, OxyContin | C4Pain ApS, Grünenthal GmbH | Osteoarthritic Knee Pain. | | | | |
| Completed | 1/2 | 24 | Europe | Tapentadol 50 mg Oral Tablet, Palexia Depot (50 mg), Tramadol Hydrochloride 100 mg Extended Release Oral Tablet, Mandolgin Retard (100 mg), Placebo Oral Tablet, Calcium tablet | Frederiksberg University Hospital | Opioid Induced Motor Disturbances | 01/16 | 01/16 | | |
